Concept · Learn
Glp-1 drugs and surgery: The Guidance Changed
Glp-1 drugs and surgery no longer come with one universal stop rule. Current U.S. perioperative guidance says many low-risk patients can continue treatment, while gastroenterology guidance still suggests holding weekly agents before elective endoscopy. Delayed gastric emptying is real; whether stopping the drug prevents the much rarer outcome of pulmonary aspiration remains unsettled.
What changed in GLP-1 guidance after 2023?
GLP-1 guidance changed from a blanket pause to a risk-based plan, but that change did not erase the older hold times. In June 2023, the American Society of Anesthesiologists (ASA) advised holding daily drugs on the procedure day and weekly drugs for seven days. The 2024 multi-society guidance instead said low-risk patients may continue treatment.
The newer document asks teams to look for the dose-escalation phase, higher doses, weekly dosing, nausea, vomiting, abdominal pain, indigestion, constipation, and other conditions that slow the stomach. If risk is high and the team chooses to withhold treatment, the document concedes that the right duration is unknown and falls back to the 2023 timing. That is a softer rule, not a declaration that the concern disappeared.
Why can delayed gastric emptying matter under anesthesia?
GLP-1 receptor agonists slow the movement of food out of the stomach. That is part of how the GLP-1 drug family affects appetite and blood sugar, but anesthesia turns leftover food into a different problem: stomach contents can move backward and enter the lungs, an event called pulmonary aspiration. Routine fasting may not always guarantee an empty stomach.
The current 2026 FDA label for Ozempic says semaglutide delays gastric emptying and notes rare postmarketing aspiration reports during general anesthesia or deep sedation despite reported fasting. FDA also says the available data cannot show whether longer fasting or temporarily stopping Ozempic reduces retained contents. The warning is real; a proven prevention interval is not.
Should you stop Ozempic before surgery?
Stopping Ozempic before surgery is no longer automatic under the U.S. multi-society approach. The ASA’s current patient guidance says most patients can continue, while the prescribing, surgical, and anesthesia teams weigh stomach-emptying risk against lost glucose control or other treatment benefits. Local instructions can still be stricter.
For higher-risk cases, the options include delaying an elective procedure until dose escalation or digestive symptoms have settled, using a clear-liquid diet for at least 24 hours, checking the stomach with ultrasound where expertise exists, or using “full stomach” anesthesia precautions. Those choices depend on the procedure and the patient; a search result cannot see either one.
Should you hold semaglutide before endoscopy?
Whether to hold semaglutide before endoscopy is where the specialty disagreement becomes clearest. The 2025 ASGE position statement suggests holding daily GLP-1 drugs for at least 24 hours and weekly drugs for at least seven days before elective endoscopy. ASGE also calls for a glucose-management plan when diabetes treatment is interrupted.
New evidence gives that caution some support, but only for retained contents. In the 2026 OCULUS randomized trial, clinically significant residual stomach volume occurred in 25.0% of 28 patients who continued a GLP-1 or GLP-1/GIP drug versus 3.1% of 32 who held one dose. No patient in the 25-person endoscopy-plus-colonoscopy subgroup, which used clear liquids the day before, had that outcome. The trial was small, stopped early, excluded general anesthesia, and did not show more aspiration or other adverse events.
What does the human evidence say about GLP-1 anesthesia aspiration?
GLP-1 anesthesia aspiration evidence has two different rungs: retained stomach contents are repeatedly observed, while actual aspiration has not risen consistently in large elective-procedure datasets. Treating those endpoints as interchangeable makes the evidence look tidier than it is. The evidence-grading framework keeps the distinction visible.
| Claim | Best current human evidence | Honest tier |
|---|---|---|
| GLP-1 drugs can leave more stomach contents at endoscopy | Randomized trial plus multiple endoscopy cohorts | Direct human evidence |
| GLP-1 drugs increase aspiration around routine elective procedures | Large retrospective studies give mixed or null results | Human observational, uncertain |
| Seven days is the proven best hold for weekly drugs | No aspiration-powered randomized trial establishes this interval | Expert consensus |
A 2025 study of 366,476 surgical patients found no significant association between preoperative GLP-1 use and aspiration pneumonia. A separate 43,365-person upper-endoscopy cohort also found no increased aspiration compared with SGLT-2 drugs, although procedure discontinuation was about twice as likely. Rare harm, imperfect billing-code outcomes, and different fasting practices leave room for uncertainty in both directions.
Is tirzepatide surgery guidance different?
Tirzepatide surgery guidance is not a separate safe lane. Tirzepatide activates both GIP and GLP-1 receptors, and perioperative guidance includes dual GLP-1/GIP drugs because delayed gastric emptying still matters. The same questions apply: dose escalation, digestive symptoms, weekly dosing, other causes of slow stomach emptying, procedure type, and depth of sedation.
The 2026 randomized endoscopy trial grouped GLP-1 and GLP-1/GIP agonists together; it did not prove a tirzepatide-specific aspiration rate. Claims that tirzepatide must always be stopped, or never needs to be stopped, both outrun that evidence. The drug name matters less than the individual risk pattern and the procedure team’s plan.
What should be confirmed before the procedure?
GLP-1 drugs and surgery require one plan shared by the prescriber, proceduralist, and anesthesia team. The useful details are the exact drug, daily or weekly schedule, last dose, reason for treatment, recent dose increases, digestive symptoms, diabetes medicines, and whether the procedure uses local anesthesia, moderate sedation, deep sedation, or general anesthesia.
Medication changes belong in that plan, especially when stopping treatment could disrupt glucose control. Ask which society or hospital protocol the team follows, whether a 24-hour liquid diet applies, and what happens if the medication was not held. That is the 2026 state of glp-1 drugs and surgery: two competent teams can give different answers because the societies still do. The honest response is coordination, not pretending the disagreement has already been settled.